Patents Assigned to Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
  • Patent number: 10933038
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: March 2, 2021
    Assignees: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren
  • Publication number: 20200281916
    Abstract: The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 ?M, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.
    Type: Application
    Filed: June 19, 2019
    Publication date: September 10, 2020
    Applicant: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Shan CEN, Quanjie LI, Dongrong YI, Yi SHI, Han WANG, Jinming ZHOU
  • Publication number: 20190274979
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Application
    Filed: November 24, 2016
    Publication date: September 12, 2019
    Applicants: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren
  • Patent number: 10252987
    Abstract: Provided are a new aromatic cyanogen compound and a preparation method thereof. The present invention also relates to the use of such compound in antiviral drugs, in particular the use thereof in anti-HCV drugs.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 9, 2019
    Assignee: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Yanping Li, Zhuorong Li, Zonggen Peng, Jianrui Li, Xinbei Jiang, Jinhua Chen, Jiandong Jiang
  • Publication number: 20180333376
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Application
    Filed: November 24, 2016
    Publication date: November 22, 2018
    Applicants: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren
  • Patent number: 9682954
    Abstract: The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: June 20, 2017
    Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, CAS, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Xiaojiang Hao, Duozhi Chen, Lin Li, Zonggen Peng, Jiandong Jiang, Yingtong Di, Junlin Yin, Sheng Wang, Jieyun Cai
  • Patent number: 9616086
    Abstract: The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.
    Type: Grant
    Filed: January 26, 2014
    Date of Patent: April 11, 2017
    Assignee: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Bin Hong, Li Wang, Xiaojian Jia, Huajun Jiang, Yu Du, Fan Yang, Shuyi Si
  • Patent number: 9359298
    Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: June 7, 2016
    Assignee: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Zhuorong Li, Xingyue Ji, Situ Xue, Guanghui Zheng, Yuhuan Li, Peizhen Tao, Jiandong Jiang
  • Publication number: 20160089390
    Abstract: The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.
    Type: Application
    Filed: January 26, 2014
    Publication date: March 31, 2016
    Applicant: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Bin HONG, Li WANG, Xiaojian JIA, Huajun JIANG, Yu DU, Fan YANG, Shuyi SI
  • Patent number: 8710098
    Abstract: A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: April 29, 2014
    Assignee: Institute of Medicinal Biotechnology Chinese Academy of Medical Science
    Inventors: Jian-Dong Jiang, Liyan Yu, Shan Cen, Zhuorong Li, Yanping Li, Jian Xu
  • Publication number: 20130190345
    Abstract: The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/or AIDS.
    Type: Application
    Filed: April 29, 2011
    Publication date: July 25, 2013
    Applicants: CSPC Zongqi Pharmaceutical Technology (Shijiahuang) Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Jiandong Jiang, Danqing Song, Nana Du, Zonggen Peng, Yuping Wang, Limei Gao, Yanxing Han, Xin Li, Chunxin Li
  • Publication number: 20100311694
    Abstract: A set of geldanamycin derivatives and their preparation methods. Pharmaceutical compositions comprising the said compounds as an active ingredient which are used as antivirus and antitumor agents. The said derivatives are used in the manufacture of heat shock protein 90 (Hsp 90) inhibiting agents which have the utility as antivirus and antitumor agents.
    Type: Application
    Filed: January 19, 2009
    Publication date: December 9, 2010
    Applicant: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Zhuorong Li, Zonggen Peng, Yanping Li, Jianhua Zhu, Peizhen Tao, Bo Fan, Yuping Wang, Guangzhi Shan, Shuqin Wang, Tian Zhang, Jiandong Jiang
  • Publication number: 20080044412
    Abstract: The present invention relates to a novel antibody-based targeting drug—a single domain antibody energized fusion protein VH-LDP-AE with potent cancer cell killing activity, anti-angiogenic activity, and anti-cancer therapeutic efficacy, to a method for producing the same, and use thereof in manufacture of an anti-tumor medicament.
    Type: Application
    Filed: April 19, 2005
    Publication date: February 21, 2008
    Applicant: INSTITUTE OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Qingfang Miao, Shuzhen Chen, Yongsu Zhen, Boyang Shang, Xiujun Liu, Xiaoyun Liu
  • Patent number: 5804567
    Abstract: A method for treating cancer in a patient by administering to a patient an nti-cancer effective amount of an anti-metabolite selected from the group consisting of 1-.beta.-arabinofuranosylcytosine and 4-amino-4-deoxy-10-methylfolic acid and an anti-oxidant effective amount of a tea polyphenol compound selected from the group consisting of a tea catechin, a theaflavin and a combination of a tea catechin and a theaflavin.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: September 8, 1998
    Assignees: Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Mitsui Norin Co., Ltd.
    Inventors: Shu Jun Cheng, De Chang Wang, Yong Su Zhen, Hoyoku Nishino, Yukihiko Hara